论文部分内容阅读
１４３例脑衰弱综合征患者随机分成舒血宁组和对照组，进行双盲的前瞻性研究。通过脑衰弱量表，打洞试验，连线实验的回查，结果表明：应用舒血宁治疗脑衰弱综合征，整体疗效明显优于对照组，脑衰弱量表的总评分显著优于对照组，而且对脑衰弱量表各个症状都有显著改善，易激惹，烦恼两项症状降分幅度较大，打洞、连线试验表明舒血宁治疗后患者的注意力、记忆力都有明显的改善，而且没有发现明显副作用。作者认为舒血宁治疗脑衰弱综合征有显著的作用，作为一种治疗脑血管疾患伴发精神症状和早期预防脑血管痴呆的新药是可行的。
143 cases of patients with brain weakness syndrome were randomly divided into Shuxuening group and control group, double-blind prospective study. Through the brain weakness scale, hole test and connection experiment, the results showed that the application of Shuxuening treatment of cerebral weakness syndrome, the overall efficacy was significantly better than the control group, the total score of the brain weakness scale was significantly better than the control group , But also for all symptoms of brain weakness scale have significantly improved, irritability, troubles two symptoms drop a large margin, holes, connection test showed Shuxuening patients after treatment, attention and memory are obvious Improve, and found no obvious side effects. The authors believe that Shuxuening treatment of cerebral debilitating syndrome has a significant role, as a treatment of cerebrovascular disease associated with psychiatric symptoms and early prevention of new drugs for cerebral vascular dementia is feasible.